Lexeo Therapeutics (LXEO) Shares Outstanding (2022 - 2026)

Lexeo Therapeutics has reported Shares Outstanding (Entity) for 5 years, with the latest figure at $74.1 million in Q1 2026.

• Quarterly Shares Outstanding (Entity) rose 123.21% year-over-year to $74.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $74.1 million (up 123.21% YoY) and the FY2025 annual result came in at $53.6 million, up 62.21% from the prior year.
• Shares Outstanding (Entity) advanced to $74.1 million in Q1 2026 per LXEO's latest filing, from $53.6 million in the prior quarter.
• Over five years, Shares Outstanding (Entity) peaked at $74.1 million in Q1 2026 and troughed at $1.6 million in Q3 2022.
• A 5-year average of $27.0 million and a median of $33.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
• The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Entity) jumped 1940.15% in 2024, then increased 0.8% in 2025.
• Over 5 years, Shares Outstanding (Entity) stood at $1.6 million in 2022, then soared by 233.15% to $5.4 million in 2023, then jumped by 517.65% to $33.1 million in 2024, then jumped by 62.21% to $53.6 million in 2025, then soared by 38.1% to $74.1 million in 2026.
• According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $74.1 million, $53.6 million, and $54.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.